Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Predictive biomarkers for T-DXd response in metastatic breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, comments on a quantitative pre-treatment evaluation of HER2 and topoisomerase 1 (Topo1) expression as predictors of response to trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer. Using HER2DX and RPPA assays, higher HER2 mRNA and protein levels were associated with longer time to next treatment in both HER2-positive and HER2-negative disease. Conversely, elevated Topo1 protein levels correlated with poorer outcomes in HER2-negative cases, supporting biomarker-driven treatment strategies. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.